Endo (ENDP) Q3 Earnings: Will The Stock Pull A Surprise?
Zacks Investment Research | Nov 02, 2016 09:49PM ET
Endo International plc (NASDAQ:ENDP) is scheduled to report third-quarter 2016 results on Nov 8, before the opening bell. The company has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 6.66%.
Last quarter, the company delivered a positive earnings surprise 14.67%. Will Endo surpass expectations this time around as well?
Let's see how things are shaping up for this quarter.
Factors Influencing This Quarter
On the second-quarter 2016 earnings call, Endo announced that it expects a sequential decline in its third-quarter results. For the third quarter, the company anticipates earnings in the range of 77–82 cents per share on revenues of $830 million to $870 million.
The anticipated decline reflects a number of factors including product order timing benefits seen in the prior quarter, which will reverse in this time, lower U.S. branded sales related to generic competition for Voltaren Gel, continued slowdown in the testosterone market, persistent declines in legacy pain products, increased investment in R&D, and higher promotional efforts related to Xiaflex and Belbuca.
Endo’s Generics base business continued to be under pressure with revenues declining approximately 5% sequentially in the second quarter of 2016, due to consortium pricing pressures and additional competitive entrants.
Endo’s Branded segment is also facing pressure due to stiff competition, and a number of public policy and regulatory actions including the recent CDC guidelines related to opioid prescribing and use. The company continues to witness pressure in terms of prescription volumes in the opioid space.
On the third-quarter call, investors are expected to focus on the company’s performance. Updates on its restructuring efforts across the Generics product and R&D portfolio, as well as its manufacturing facility network should also be awaited keenly.
Earnings Whispers
Our proven model does not conclusively show that Endo is likely to beat earnings this quarter. This is because a stock needs to have both a positive Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.